Expression of the transcription factor LMO2 in more than half of DLBCL patients is thought to prevent the recruitment of BRCA1, leading to the BRCAness phenotype and hypersensitivity to PARPi. The gene discussed is LMO2; the disease is diffuse large B-cell lymphoma.